Terminated PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT00764699

Effect of Increlex® on Children With Crohn Disease

Sponsor: Nationwide Children's Hospital

Updated 7 times since 2017 Last updated: Feb 23, 2018 Started: Oct 31, 2008 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

PI left institution

Other terminated trials from Nationwide Children's Hospital

See all terminations from Nationwide Children's Hospital

Other Crohn Disease trials with similar outcome

Browse all Crohn Disease trials

Listed as NCT00764699, this PHASE2/PHASE3 trial focuses on Crohn Disease and remains terminated or withdrawn. Sponsored by Nationwide Children's Hospital, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3
Mar 2018 — Jun 2018 [monthly]

Terminated PHASE2_PHASE3

▶ Show 2 earlier versions

Feb 2017 — Mar 2018 [monthly]

Terminated PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2_PHASE3

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nationwide Children's Hospital
Tercica

Data source: Nationwide Children's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States